135 related articles for article (PubMed ID: 9521054)
1. Suppression of IL-12 production by phosphodiesterase inhibition in murine endotoxemia is IL-10 independent.
Haskó G; Szabó C; Németh ZH; Salzman AL; Vizi ES
Eur J Immunol; 1998 Feb; 28(2):468-72. PubMed ID: 9521054
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
Seldon PM; Barnes PJ; Giembycz MA
Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
[TBL] [Abstract][Full Text] [Related]
3. The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice.
Liang L; Beshay E; Prud'homme GJ
Diabetes; 1998 Apr; 47(4):570-5. PubMed ID: 9568689
[TBL] [Abstract][Full Text] [Related]
4. Effect of the phosphodiesterase III inhibitor amrinone on cytokine and nitric oxide production in immunostimulated J774.1 macrophages.
Németh ZH; Szabó C; Haskó G; Salzman AL; Vizi ES
Eur J Pharmacol; 1997 Nov; 339(2-3):215-21. PubMed ID: 9473138
[TBL] [Abstract][Full Text] [Related]
5. Effects of rolipram, a selective inhibitor of type 4 phosphodiesterase, on lipopolysaccharide-induced uveitis in rats.
Chi ZL; Hayasaka S; Zhang XY; Hayasaka Y; Cui HS
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2497-502. PubMed ID: 15277469
[TBL] [Abstract][Full Text] [Related]
6. Amrinone and theophylline differentially regulate cytokine and nitric oxide production in endotoxemic mice.
Németh ZH; Haskó G; Szabó C; Vizi ES
Shock; 1997 May; 7(5):371-5. PubMed ID: 9165673
[TBL] [Abstract][Full Text] [Related]
7. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H
Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165
[TBL] [Abstract][Full Text] [Related]
8. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation.
Sekut L; Yarnall D; Stimpson SA; Noel LS; Bateman-Fite R; Clark RL; Brackeen MF; Menius JA; Connolly KM
Clin Exp Immunol; 1995 Apr; 100(1):126-32. PubMed ID: 7697910
[TBL] [Abstract][Full Text] [Related]
9. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
[TBL] [Abstract][Full Text] [Related]
10. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor.
Prabhakar U; Lipshutz D; Bartus JO; Slivjak MJ; Smith EF; Lee JC; Esser KM
Int J Immunopharmacol; 1994 Oct; 16(10):805-16. PubMed ID: 7843852
[TBL] [Abstract][Full Text] [Related]
11. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages.
Kambayashi T; Jacob CO; Zhou D; Mazurek N; Fong M; Strassmann G
J Immunol; 1995 Nov; 155(10):4909-16. PubMed ID: 7594495
[TBL] [Abstract][Full Text] [Related]
12. Neutralization of IL-18 reduces neutrophil tissue accumulation and protects mice against lethal Escherichia coli and Salmonella typhimurium endotoxemia.
Netea MG; Fantuzzi G; Kullberg BJ; Stuyt RJ; Pulido EJ; McIntyre RC; Joosten LA; Van der Meer JW; Dinarello CA
J Immunol; 2000 Mar; 164(5):2644-9. PubMed ID: 10679104
[TBL] [Abstract][Full Text] [Related]
13. Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4.
Miotla JM; Teixeira MM; Hellewell PG
Am J Respir Cell Mol Biol; 1998 Mar; 18(3):411-20. PubMed ID: 9490659
[TBL] [Abstract][Full Text] [Related]
14. Suppression of anti-CD3-induced interleukin-4 and interleukin-5 release from splenocytes of Mesocestoides corti-infected BALB/c mice by phosphodiesterase 4 inhibitors.
Souness JE; Houghton C; Sardar N; Withnall MT
Biochem Pharmacol; 1999 Sep; 58(6):991-9. PubMed ID: 10509751
[TBL] [Abstract][Full Text] [Related]
15. Regulation of lipopolysaccharide sensitivity by IFN regulatory factor-2.
Cuesta N; Salkowski CA; Thomas KE; Vogel SN
J Immunol; 2003 Jun; 170(11):5739-47. PubMed ID: 12759457
[TBL] [Abstract][Full Text] [Related]
16. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.
Griswold DE; Webb EF; Badger AM; Gorycki PD; Levandoski PA; Barnette MA; Grous M; Christensen S; Torphy TJ
J Pharmacol Exp Ther; 1998 Nov; 287(2):705-11. PubMed ID: 9808700
[TBL] [Abstract][Full Text] [Related]
17. Difference in preventive effects between the phosphodiesterase iv inhibitor rolipram and anti-arthritic drugs on antigen-induced arthritis in mice.
Yamaki K; Li X; Hossain MA; Alam AH; Taneda S; Yanagisawa R; Takano H; Yoshino S
Immunol Invest; 2007; 36(2):131-45. PubMed ID: 17365015
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
[TBL] [Abstract][Full Text] [Related]
19. Effects of inhibition of PDE4 and TNF-alpha on local and remote injuries following ischaemia and reperfusion injury.
Souza DG; Cassali GD; Poole S; Teixeira MM
Br J Pharmacol; 2001 Nov; 134(5):985-94. PubMed ID: 11682446
[TBL] [Abstract][Full Text] [Related]
20. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis.
Foey AD; Field S; Ahmed S; Jain A; Feldmann M; Brennan FM; Williams R
Arthritis Res Ther; 2003; 5(6):R317-28. PubMed ID: 14680506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
